Oral Transmucosal Cannabidiol Oil Formulation as Part of a Multimodal Analgesic Regimen: Effects on Pain Relief and Quality of Life Improvement in Dogs Affected by Spontaneous Osteoarthritis.
Oral Transmucosal Cannabidiol Oil Formulation as Part of a Multimodal Analgesic Regimen: Effects on Pain Relief and Quality of Life Improvement in Dogs Affected by Spontaneous Osteoarthritis.
复制标题
DOI：
10.3390/ani10091505
复制
发表时间：
2020-08-26
期刊：
影响因子：
--
通讯作者：
Ravasio G
中科院分区：
文献类型：
--
作者：
Brioschi FA;Di Cesare F;Gioeni D;Rabbogliatti V;Ferrari F;D'Urso ES;Amari M;Ravasio G
骨关节炎是一种进行性和退行性疾病，影响狗群，引起疼痛。与骨关节炎相关的疼痛被认为是慢性的，由于活动性炎症和中枢致敏引起的不适应成分。狗的慢性疼痛越来越被认为是一个重要的问题，找到成功的治疗犬骨关节炎相关疼痛的方法是具有挑战性的。本研究的目的是评估在12周的时间内口服经黏膜大麻二酚与多模式药理学方案相结合对自发性骨关节炎犬的疼痛管理效果。与未接受大麻二酚治疗的狗相比，接受经黏膜口服大麻二酚以及抗炎药加巴喷丁和阿米替林治疗的狗在犬短暂疼痛量表评分上有显著改善。目前的研究表明，在犬骨关节炎的多模式药物治疗中加入经黏膜口服大麻二酚可以改善饲主报告的疼痛评分和狗的生活质量，没有严重的不良反应。本研究的目的是评估口服经黏膜（OTM）大麻二酚（CBD）在多模式药物治疗犬慢性骨关节炎相关疼痛的疗效。21只狗随机分为两组：CBD组（n = 9），治疗方案中加入OTM CBD（每12 h 2 mg kg - 1）（抗炎药、加巴喷丁、阿米替林），C组（n = 12）不给予CBD。治疗开始前（T0）和治疗后1周（T1）、2周（T2）、4周（T3）和12周（T4），由饲主根据犬短暂疼痛量表评分系统对狗进行评估。CBD组疼痛严重程度评分在T1 （p = 0.0002）、T2 （p = 0.0043）和T3 （p = 0.016）显著低于C组。CBD组疼痛干扰评分在T1 （p = 0.0002）、T2 （p = 0.0007）和T4 （p = 0.004）时显著低于C组。在T1时，CBD组的生活质量指数显著高于对照组（p = 0.003）。加入OTM CBD效果良好。需要进一步的药代动力学和更大人群的长期研究，以鼓励将其纳入犬骨关节炎相关疼痛的多模式药理学方法。
Osteoarthritis is a progressive and degenerative condition that affects dog populations, causing pain. The pain associated with osteoarthritis is considered to be chronic, owing to both active inflammation and to a maladaptive component caused by central sensitization. Chronic pain in dogs is being increasingly recognised as a significant problem, and finding successful treatments against canine osteoarthritis-related pain is challenging. The aim of this study was to assess the efficacy in pain management over a twelve-week period of oral transmucosal cannabidiol, in combination with a multimodal pharmacological protocol, in dogs affected by spontaneous osteoarthritis. Dogs receiving oral transmucosal cannabidiol in addition to an anti-inflammatory drug, gabapentin and amitriptyline showed a meaningful improvement in Canine Brief Pain Inventory scores, in comparison with dogs that did not receive cannabidiol. The present study suggests that the addition of oral transmucosal cannabidiol to a multimodal pharmacological treatment for canine osteoarthritis improves owner reported pain scores and quality of life of dogs, without severe adverse effects. The aim of this study was to evaluate the efficacy of oral transmucosal (OTM) cannabidiol (CBD), in addition to a multimodal pharmacological treatment for chronic osteoarthritis-related pain in dogs. Twenty-one dogs were randomly divided into two groups: in group CBD (n = 9), OTM CBD (2 mg kg−1 every 12 h) was included in the therapeutic protocol (anti-inflammatory drug, gabapentin, amitriptyline), while in group C (n = 12), CBD was not administered. Dogs were evaluated by owners based on the Canine Brief Pain Inventory scoring system before treatment initiation (T0), and one (T1), two (T2), four (T3) and twelve (T4) weeks thereafter. Pain Severity Score was significantly lower in CBD than in C group at T1 (p = 0.0002), T2 (p = 0.0043) and T3 (p = 0.016). Pain Interference Score was significantly lower in CBD than in C group at T1 (p = 0.0002), T2 (p = 0.0007) and T4 (p = 0.004). Quality of Life Index was significantly higher in CBD group at T1 (p = 0.003). The addition of OTM CBD showed promising results. Further pharmacokinetics and long-term studies in larger populations are needed to encourage its inclusion into a multimodal pharmacological approach for canine osteoarthritis-related pain.
登录
查看更多内容
影响因子：
7.4
作者：
Ivanavicius, Stefan P.;Ball, Adrian D.;Read, Simon J.
通讯作者：
Read, Simon J.
影响因子：
1.3
作者：
Di Cesare, Federica;Gioeni, Daniela;Cagnardi, Petra
通讯作者：
Cagnardi, Petra
影响因子：
3.2
作者：
Gamble, Lauri-Jo;Boesch, Jordyn M.;Wakshlag, Joseph J.
通讯作者：
Wakshlag, Joseph J.
DOI：
10.2460/javma.243.9.1291
发表时间：
2013-11-01
影响因子：
1.9
作者：
Fahie, Maria A.;Ortolano, Girolamo A.;Bertone, Alicia L.
通讯作者：
Bertone, Alicia L.
影响因子：
5.6
作者：
Devinsky O;Cilio MR;Cross H;Fernandez-Ruiz J;French J;Hill C;Katz R;Di Marzo V;Jutras-Aswad D;Notcutt WG;Martinez-Orgado J;Robson PJ;Rohrback BG;Thiele E;Whalley B;Friedman D
通讯作者：
Friedman D